Actively Recruiting
PROTECT-HIE Pilot Trial Evaluating Early Dobutamine Use During Cooling in Newborns with Hypoxic-Ischemic Encephalopathy
Led by University of Alberta · Updated on 2026-10-20
40
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Some newborns experience a lack of oxygen and blood flow around the time of birth, leading to a serious condition called hypoxic-ischemic encephalopathy HIE. This condition can cause brain and organ injury, including to the heart. Researchers are studying whether starting a heart-supporting medicine called dobutamine early during standard cooling treatment can be done safely and help improve outcomes for these babies. In this study, 40 newborns with HIE receiving therapeutic hypothermia will be randomly assigned to receive either a low dose of dobutamine or a placebo within four hours of starting cooling. The dobutamine infusion will continue until the babys condition improves, the medicine is no longer needed, or more heart support is required. The study is double-blinded, so families and medical staff will not know which treatment the baby receives. Heart function will be assessed using echocardiography during the first 48 hours. Participants will be closely monitored during their hospital stay. Researchers will collect data on brain injury signs seen on MRI, seizure activity, heart function, need for extra heart medications, blood marker recovery, urine output, length of hospitalization, and survival. The main goal is to see if early dobutamine use is feasible and safe, with results helping to guide future larger trials to improve care for babies with HIE.
CONDITIONS
Brief Title
The PROTECT-HIE Pilot Trial
Research Team
A
Aimann Surak, MD FRCPC DRCPSC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here